STAT

Tom Marsilje, a relentless advocate for cancer patients, dies at 45

Tom Marsilje was eternally optimistic and willing to give of his time to help his fellow cancer patients find clinical trials and experimental therapies.

When Tom Marsilje launched a website in May to help people with late-stage colorectal cancer find possible treatments through clinical trials, he pointed out the irony: “The ultimate CRC clinical trial advocate is unlikely to ever do a clinical trial,” he said.

He was right.

Marsilje, a Novartis scientist who helped develop a cutting-edge lung cancer treatment — and who, after his own colon cancer diagnosis, became a fierce advocate for his fellow patients — died Tuesday afternoon at a hospital in San Diego. He was 45.

The cancer support community was reeling in the wake of the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks